Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2013-07-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1301455110PMID 23842089PMCID PMC3732982
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• mTOR signaling in growth control and disease.

  2012cited by this paper
• Role of PRAS 40 in Akt and mTOR signaling in health and disease

  2012cited by this paper
• Orai1 deficiency leads to heart failure and skeletal myopathy in zebrafish

  2012cited by this paper
• Preservation of Myocardial Structure Is Enhanced by Pim-1 Engineering of Bone Marrow Cells

  2012cited by this paper
• Role of PRAS40 in Akt and mTOR signaling in health and disease.

  2012cited by this paper
• Cardiac Progenitor Cell Commitment Is Inhibited by Nuclear Akt Expression

  2011cited by this paper
• Heart Failure 1 In search of new therapeutic targets and strategies for heart failure : recent advances in basic science

  2011cited by this paper
• Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

  2011cited by this paper
• Nucleolar stress is an early response to myocardial damage involving nucleolar proteins nucleostemin and nucleophosmin

  2011cited by this paper
• AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.

  2011cited by this paper
• SUMO1-dependent modulation of SERCA2a in heart failure

  2011cited by this paper
• The Inotropic Peptide &bgr;ARKct Improves &bgr;AR Responsiveness in Normal and Failing Cardiomyocytes Through G&bgr;&ggr;-Mediated L-Type Calcium Current Disinhibition

  2011cited by this paper
• Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress.

  2010cited by this paper
• Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies.

  2010cited by this paper
• Erythropoietin Activates Mitochondrial Biogenesis and Couples Red Cell Mass to Mitochondrial Mass in the Heart

  2010cited by this paper
• mTOR: from growth signal integration to cancer, diabetes and ageing

  2010cited by this paper
• The Inotropic Peptide (cid:1) ARKct Improves (cid:1) AR Responsiveness in Normal and Failing Cardiomyocytes Through G (cid:1)(cid:2) -Mediated L-Type Calcium Current Disinhibition

  2010cited by this paper
• Beneficial effects of Mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction.

  2009cited by this paper
• Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin.

  2009cited by this paper
• Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

  2009cited by this paper
• The binding of PRAS40 to 14-3-3 proteins is not required for activation of mTORC1 signalling by phorbol esters/ERK.

  2008cited by this paper
• Pim-1 kinase antagonizes aspects of myocardial hypertrophy and compensation to pathological pressure overload

  2008cited by this paper
• PRAS40 Is a Target for Mammalian Target of Rapamycin Complex 1 and Is Required for Signaling Downstream of This Complex*

  2007influential reference
• Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface

  2007cited by this paper
• The Proline-rich Akt Substrate of 40 kDa (PRAS40) Is a Physiological Substrate of Mammalian Target of Rapamycin Complex 1*

  2007influential reference
• PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding*

  2007cited by this paper
• Adeno-associated virus-mediated expression of thyroid hormone receptor isoforms-alpha1 and -beta1 improves contractile function in pressure overload-induced cardiac hypertrophy.

  2007cited by this paper
• PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase.

  2007cited by this paper
• Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins.

  2007cited by this paper
• Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

  2007influential reference
• Abstract 1523: Pim-1 Regulates Cardiomyocyte Survival Downstream of Akt

  2006cited by this paper
• Insulin-Mediated Phosphorylation of the Proline-Rich Akt Substrate PRAS40 Is Impaired in Insulin Target Tissues of High-Fat Diet–Fed Rats

  2006cited by this paper
• Large-scale characterization of HeLa cell nuclear phosphoproteins.

  2004cited by this paper
• Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload

  2004cited by this paper
• Hypertrophy of the heart: a new therapeutic target?

  2004cited by this paper
• Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy

  2003cited by this paper
• Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner*

  2003cited by this paper
• Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress

  2002cited by this paper

• High glucose couples DJ-1 with PTEN to activate PDGFRβ for renal proximal tubular cell injury

  2025cites this paper
• ABCC9 knockdown attenuates isoproterenol-induced myocardial hypertrophy by inhibiting the PI3K/AKT signaling pathway

  2025cites this paper
• Design and pharmacodynamic study of live biotherapeutic products with efficient degradation of branched‐chain amino acids

  2025cites this paper
• Intensity, Duration, and Context Dependency of the Responses to Nutrient Surplus and Deprivation Signaling in the Heart: Insights Into the Complexities of Cardioprotection

  2025cites this paper
• Translational Control in Cardiac Pathophysiology and Therapeutic Development: When mRNA Meets the Heart

  2025cites this paper
• Research progress on programmed cell death of cardiomyocytes in pressure-overload hypertrophic cardiomyopathy

  2025cites this paper
• Investigating the Mechanistic Target of Rapamycin and Analogous Pathways in Cardiovascular Diseases to Augment Cardiac Functionality

  2025cites this paper
• Expression of PIM1/ASK1 Molecular Pathway Related Genes in Ischemic Cardiomyopathy.

  2025cites this paper
• Dual Translational Control in Cardiomyocytes by Heterogeneous mTORC1 and Hypertrophic ERK Activation

  2025cites this paper
• A novel uORF regulates folliculin to promote cell growth and lysosomal biogenesis during cardiac stress

  2025cites this paper
• Stage-specific regulation of undifferentiated spermatogonia by AKT1S1-mediated AKT-mTORC1 signaling during mouse spermatogenesis.

  2024cites this paper
• Sestrin2 serves as a scaffold protein to maintain cardiac energy and metabolic homeostasis during pathological stress

  2024cites this paper
• High glucose-induced downregulation of PTEN-Long is sufficient for proximal tubular cell injury in diabetic kidney disease.

  2024cites this paper
• Exploiting new strategies in combating head and neck carcinoma: A comprehensive review on phytochemical approaches passing through PI3K/Akt/mTOR signaling pathway

  2024cites this paper
• The protective role of plant-derived proteins in Mediterranean diet against chronic non-communicable diseases

  2024cites this paper
• RNA-binding proteins in cardiovascular biology and disease: the beat goes on

  2024cites this paper
• Keeping the Heart Healthy: The Role of Exercise in Cardiac Repair and Regeneration

  2023cites this paper
• mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy

  2023cites this paper
• Anti-inflammatory, Anti-fibrotic and Pro-cardiomyogenic Effects of Genetically Engineered Extracellular Vesicles Enriched in miR-1 and miR-199a on Human Cardiac Fibroblasts

  2023cites this paper
• Industrial pollutans and epigenetic factors associated with cardiomyopathies

  2023cites this paper
• Interaction Between CD34+ Fibrocytes and Airway Smooth Muscle Promotes IL-8 Production and Akt/PRAS40/mTOR Signaling in Asthma

  2022cites this paper
• Targeting mTOR Signaling in Type 2 Diabetes Mellitus and Diabetes Complications.

  2022cites this paper
• Targeting PRAS40: a novel therapeutic strategy for human diseases

  2021cites this paper
• Thymoquinone ameliorates pressure overload‐induced cardiac hypertrophy by activating the AMPK signalling pathway

  2021cites this paper
• Hallmarks of exercised heart.

  2021cites this paper
• Circadian Regulation of Autophagy in the Heart Via the mTOR Pathway

  2021cites this paper
• Pharmacological Inhibition of Mammalian Target of Rapamycin Attenuates Deoxycorticosterone Acetate Salt–Induced Hypertension and Related Pathophysiology: Regulation of Oxidative Stress, Inflammation, and Cardiovascular Hypertrophy in Male Rats

  2021cites this paper
• Cardiac aging

  2021cites this paper
• AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo

  2021cites this paper
• Muscle‐specific Cand2 is translationally upregulated by mTORC1 and promotes adverse cardiac remodeling

  2021cites this paper
• N6-Methyladenosine in the Heart

  2021cites this paper
• Inhibition of Mammalian Target of Rapamycin Attenuates Recurrent Seizures Associated Cardiac Damage in a Zebrafish Kindling Model of Chronic Epilepsy

  2021cites this paper
• Fetal Gene Reactivation in Pulmonary Arterial Hypertension: GOOD, BAD, or BOTH?

  2021cites this paper
• Metabolic remodeling precedes mTORC1-mediated cardiac hypertrophy.

  2021cites this paper
• Relevance of N6-methyladenosine regulators for transcriptome: Implications for development and the cardiovascular system.

  2021cites this paper
• Identification of dynamic RNA-binding proteins uncovers a Cpeb4-controlled regulatory cascade during pathological cell growth of cardiomyocytes.

  2021cites this paper
• AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo

  2021cites this paper
• Therapeutic Delivery of Pip4k2c‐Modified mRNA Attenuates Cardiac Hypertrophy and Fibrosis in the Failing Heart

  2021cites this paper
• Commentary: SGLT2 inhibitors reduce mortality and heart failure in patients with type 2 diabetes mellitus-is metabolic reprogramming the mechanism for these favorable outcomes?

  2021cites this paper
• Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition?

  2021cites this paper
• The complex network of mTOR signaling in the heart.

  2021cites this paper
• The Molecular Landscape and Biological Alterations Induced by PRAS40-Knockout in Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• Mechanical Regulation of Protein Translation in the Cardiovascular System

  2020cites this paper
• Translating Translation to Mechanisms of Cardiac Hypertrophy

  2020cites this paper
• Saraf-dependent activation of mTORC1 regulates cardiac growth.

  2020cites this paper
• Unfolded protein response in cardiovascular disease.

  2020cites this paper
• The Lysosome at the Intersection of Cellular Growth and Destruction.

  2020cites this paper
• A multi-network comparative analysis of transcriptome and translatome in cardiac remodeling

  2020cites this paper
• Substrate metabolism regulated by Sestrin2–mTORC1 alleviates pressure overload-induced cardiac hypertrophy in aged heart

  2020cites this paper
• mTORC1 activation contributes to autophagy inhibition via its recruitment to lysosomes and consequent lysosomal dysfunction in cadmium-exposed rat proximal tubular cells.

  2020cites this paper
• THE STUDY OF THE ACTIVATION OF MTORC1 AND ITS SUBSTRATE P70S6K INVOLVED IN TYPE 2 DIABETES MELLITUS AND ONCOGENETIC PROCESSES

  2020cites this paper
• A Multi-Network Comparative Analysis of Transcriptome and Translatome Identifies Novel Hub Genes in Cardiac Remodeling

  2020cites this paper
• Muscle specific translational control of Cand2 by mTORC1 regulates adverse cardiac remodeling

  2020cites this paper
• ATF6 Regulates Cardiac Hypertrophy by Transcriptional Induction of the mTORC1 Activator, Rheb

  2019cites this paper
• STAT3-miR-17/20 Signaling Axis Plays a Critical Role in Attenuating Myocardial Infarction following Rapamycin Treatment in Diabetic mice.

  2019cites this paper
• PRAS40 suppresses atherogenesis through inhibition of mTORC1-dependent pro-inflammatory signaling in endothelial cells

  2019cites this paper
• Testosterone deficiency reduces cardiac hypertrophy in a rat model of severe volume overload

  2019cites this paper
• A high-throughput ratiometric method for imaging hypertrophic growth in cultured primary cardiac myocytes

  2019cites this paper
• m6A-mRNA methylation regulates cardiac gene expression and cellular growth

  2019cites this paper
• mTORC1 and mTORC2 Differentially Regulate Cell Fate Programs to Coordinate Osteoblastic Differentiation in Mesenchymal Stromal Cells

  2019cites this paper
• Identification and Characterization of Two Novel Oncogenic mTOR Mutations

  2019cites this paper
• Branched Chain Amino Acids.

  2019cites this paper
• microRNA‐181a downregulates deptor for TGF&bgr;‐induced glomerular mesangial cell hypertrophy and matrix protein expression

  2018cites this paper
• Fisetin inhibits cardiac hypertrophy by suppressing oxidative stress.

  2018cites this paper
• New Insights Into the Role of mTOR Signaling in the Cardiovascular System.

  2018cites this paper
• Understanding Key Mechanisms of Exercise-Induced Cardiac Protection to Mitigate Disease: Current Knowledge and Emerging Concepts.

  2018cites this paper
• The role of Pontin in stress-induced cardiac hypertrophy

  2018cites this paper
• The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection.

  2017cites this paper
• Genomic structural variations lead to dysregulation of important coding and non‐coding RNA species in dilated cardiomyopathy

  2017cites this paper
• PRAS40 promotes NF-κB transcriptional activity through association with p65

  2017cites this paper
• Sestrin 2 attenuates neonatal rat cardiomyocyte hypertrophy induced by phenylephrine via inhibiting ERK1/2

  2017cites this paper
• MicroRNA-365 accelerates cardiac hypertrophy by inhibiting autophagy via the modulation of Skp2 expression.

  2017cites this paper
• Reperfusion Therapy with Rapamycin Attenuates Myocardial Infarction through Activation of AKT and ERK

  2017cites this paper
• Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases

  2017cites this paper
• The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus

  2017cites this paper
• Peptidyl‐Prolyl Isomerase 1 Regulates Ca2+ Handling by Modulating Sarco(Endo)Plasmic Reticulum Calcium ATPase and Na2+/Ca2+ Exchanger 1 Protein Levels and Function

  2017cites this paper
• Trimedazidine alleviates pulmonary artery banding-induced acute right heart dysfunction and activates PRAS40 in rats

  2017cites this paper
• Exercise for Cardiovascular Disease Prevention and Treatment

  2017cites this paper
• The valosin‐containing protein is a novel repressor of cardiomyocyte hypertrophy induced by pressure overload

  2017cites this paper
• Cholesterol-Lowering Gene Therapy Counteracts the Development of Non-ischemic Cardiomyopathy in Mice.

  2017cites this paper
• The "tail" of Connexin43: An unexpected journey from alternative translation to trafficking.

  2016cites this paper
• Nutrient-sensing mTORC1: Integration of metabolic and autophagic signals.

  2016cites this paper
• Tat-PRAS40 prevent hippocampal HT-22 cell death and oxidative stress induced animal brain ischemic insults.

  2016cites this paper
• Molecular Aspects of Exercise-induced Cardiac Remodeling.

  2016cites this paper
• mTOR, cardiomyocytes and inflammation in cardiac hypertrophy.

  2016cites this paper
• Quantitative Non-Canonical Amino acid Tagging based proteomics identifies distinct patterns of protein synthesis rapidly induced by hypertrophic agents in cardiomyocytes, revealing new aspects of metabolic remodeling Running title: Translational control by hypertrophic agents in heart cells

  2016cites this paper
• Targeting PRAS40 for multiple diseases.

  2016cites this paper
• Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Pathological Cardiac Hypertrophy

  2016cites this paper
• Quantitative Non-canonical Amino Acid Tagging (QuaNCAT) Proteomics Identifies Distinct Patterns of Protein Synthesis Rapidly Induced by Hypertrophic Agents in Cardiomyocytes, Revealing New Aspects of Metabolic Remodeling

  2016cites this paper
• Role of mTOR Signaling in Cardioprotection

  2016cites this paper
• PRAS40 deregulates apoptosis in Ewing sarcoma family tumors by enhancing the insulin receptor/Akt and mTOR signaling pathways.

  2016cites this paper
• Therapeutic Targeting of Autophagy: Potential and Concerns in Treating Cardiovascular Disease

  2015cites this paper
• Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets

  2015cites this paper
• Links between mTOR and the immunoproteasome: Therapeutic targets for cardiac hypertrophy?

  2015cites this paper
• Is Inhibition of Hypertrophy a Good Therapeutic Strategy in Ventricular Pressure Overload?: Inhibition of Hypertrophy, Per Se, May Not Be a Good Therapeutic Strategy in Ventricular Pressure Overload Other Approaches Could Be More Beneficial

  2015cites this paper
• Blockade of the acute activation of mTOR complex 1 decreases hypertrophy development in rats with severe aortic valve regurgitation

  2015cites this paper
• ANKYRIN-B AND mTOR COMPLEX 1 IN THE REGULATION OF ELECTRICAL ACTIVITIES IN THE HEART

  2015cites this paper
• miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation

  2015cites this paper
• Disease Therapeutic Targeting of Autophagy : Potential and Concerns in Treating Cardiovascular

  2015cites this paper
• Hrd1 and ER-Associated Protein Degradation, ERAD, are Critical Elements of the Adaptive ER Stress Response in Cardiac Myocytes.

  2015cites this paper